Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) shares passed below its fifty day moving average during trading on Monday. The stock has a fifty day moving average of $33.19 and traded as low as $32.44. Pharvaris shares last traded at $32.44, with a volume of 307,769 shares.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on PHVS shares. Wedbush boosted their target price on Pharvaris from $42.00 to $50.00 and gave the stock an “outperform” rating in a report on Wednesday, September 9th. Wells Fargo & Company upped their target price on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Guggenheim raised their target price on Pharvaris from $40.00 to $44.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. HC Wainwright reiterated a “buy” rating on shares of Pharvaris in a report on Tuesday, October 6th. Finally, Oppenheimer reissued an “outperform” rating on shares of Pharvaris in a research report on Friday, October 23rd. Fourteen research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Pharvaris has a consensus rating of “Moderate Buy” and an average target price of $59.53.
Get Our Latest Stock Analysis on Pharvaris
Pharvaris Stock Down 2.8%
The firm has a 50-day moving average of $33.19 and a two-hundred day moving average of $31.34. The company has a market capitalization of $2.12 billion, a PE ratio of -10.40 and a beta of -2.48.
Pharvaris (NASDAQ:PHVS – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.04. On average, equities research analysts expect that Pharvaris N.V. will post -3.02 EPS for the current year.
Insiders Place Their Bets
In related news, Director Johannes Gerardus Chri Schikan sold 200,000 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $35.00, for a total transaction of $7,000,000.00. Following the completion of the sale, the director owned 115,167 shares in the company, valued at $4,030,845. This represents a 63.46% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Elisabeth Bjork sold 52,500 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the transaction, the director owned 15,167 shares in the company, valued at $574,677.63. This trade represents a 77.59% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 510,810 shares of company stock worth $18,563,973.
Hedge Funds Weigh In On Pharvaris
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quantbot Technologies LP purchased a new position in shares of Pharvaris in the 2nd quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in Pharvaris during the second quarter worth about $93,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Pharvaris during the third quarter worth about $114,000. Public Employees Retirement System of Ohio acquired a new position in Pharvaris during the second quarter worth about $196,000. Finally, Algert Global LLC acquired a new position in Pharvaris during the second quarter worth about $238,000.
Pharvaris Company Profile
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks.
Further Reading
- Five stocks we like better than Pharvaris
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
